SCHEMBL5358249

SCHEMBL5358249

O=C(O)CCCN1C(=O)c2ccc3c4c(ccc(c24)C1=O)C(=O)N(CCCC(=O)O)C3=O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.73
KMT2A Q03164 3/20 0.73
GAA P10253 1/20 0.67
CASP1 P29466 1/20 0.67
HSD17B10 Q99714 1/20 0.67
SMN1; SMN2 Q16637 2/20 0.62
KDM4E B2RXH2 2/20 0.62
RGS12 O14924 1/20 0.62
NPC1 O15118 1/20 0.62
ALDH1A1 P00352 1/20 0.62
LMNA P02545 1/20 0.62
PABPC1 P11940 1/20 0.62
HTT P42858 1/20 0.62
RECQL P46063 1/20 0.62
RAB9A P51151 1/20 0.62
TERT O14746 3/20 0.54
STAT3 P40763 1/20 0.49
HIF1A Q16665 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
PTGS1 P23219 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31018799 0.92 MEN1 (0.64) MEN1KMT2AGAACASP1HSD17B10
SCHEMBL14502343 0.91 MEN1 (0.67) MEN1KMT2AGAACASP1HSD17B10
SCHEMBL3859088 0.91 MEN1 (0.65) MEN1KMT2AGAACASP1HSD17B10
SCHEMBL14023167 0.89 NPSR1 (0.60) MEN1KMT2AGAACASP1HSD17B10
SCHEMBL22018079 0.89 MEN1 (0.60) MEN1KMT2AGAACASP1HSD17B10
SCHEMBL22019037 0.87 SMN1; SMN2 (0.62) MEN1KMT2AGAACASP1HSD17B10
SCHEMBL3852253 0.85 MEN1 (0.57) MEN1KMT2AGAACASP1HSD17B10
SCHEMBL29459522 0.85 KMT2A (0.73) MEN1KMT2AGAACASP1HSD17B10
SCHEMBL877279 0.85 KMT2A (0.73) MEN1KMT2AGAACASP1HSD17B10
SCHEMBL3134908 0.85 MEN1 (1.00) MEN1KMT2AGAAHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099900-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-03 US claimed
US-7279580-B2 Imidazo-pyridine derivatives as ligands for GABA receptors MERCK SHARP & DOHME LIMITED (GB) 2007-10-09 US disclosed
US-20070099900-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-03 US disclosed
US-20070099900-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-03 US disclosed
US-20070099900-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-03 US disclosed
EP-1511747-B1 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2006-04-12 EP disclosed
US-20050165048-A1 Imidazo-pyridine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2005-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099900-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 MEN1 3865/4885KMT2A 4267/4885GAA 1774/4885
US-20050165048-A1 Imidazo-pyridine derivatives as ligands for gaba receptors GABRA3, GABRA2, GABRA5 MEN1 4452/4885KMT2A 1066/4885GAA 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.